WILMINGTON, Mass., Feb. 2 PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.((R)) , a specialty pharmaceutical company focused primarily on the development and marketing of its Levulan((R)) Photodynamic Therapy (PDT) technology platform for the prevention and treatment of dermatological skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the 12th Annual BIO CEO & Investor Conference. The conference is being held at the Waldorf Astoria Hotel in New York on February 8-9, 2010. Mr. Doman is scheduled to present at 1:00 p.m. ET on February 9, 2010. Interested parties can access the live audio webcast of the presentation at www.dusapharma.com. An archived version of the presentation will be available on the DUSA website approximately one hour following the presentation.
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan((R)) photodynamic therapy (PDT) technology platform, and other dermatology products. Levulan((R)) PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses (AKs) of the face and scalp. DUSA is researching the use of Levulan((R)) PDT to prevent AKs and squamous cell carcinomas in immunosuppressed solid organ transplant recipients and is supporting research related to oral leukoplakia in collaboration with the National Institutes of Health (NIH). DUSA also markets other dermatology products, including ClindaReach((R)). DUSA is based in Wilmington, Mass. Please visit our website at www.dusapharma.com.
CONTACT: Chad Rubin, Investor Relations, The Trout Group LLC,
+1-646-378-2947, for DUSA Pharmaceuticals, Inc.
Web site: http://www.dusapharma.com/
